Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes
Tóm tắt
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dipeptidyl peptidase‐4 (DPP‐4) inhibitors might increase the risk of intestinal obstruction, but real‐world evidence for this severe adverse event is lacking. Thus, the objective of this study was to determine whether GLP‐1 RAs and DPP‐4 inhibitors are associated with an increased risk of intestinal obstruction compared with sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors. We used the United Kingdom Clinical Practice Research Datalink and linked databases to assemble two new‐user, active comparator cohorts (2013–2019). The first included 25,617 and 67,261 GLP‐1 RA and SGLT‐2 inhibitor users, respectively. The second included 131,927 and 40,615 DPP‐4 inhibitor and SGLT‐2 inhibitor users, respectively. Propensity score fine stratification weighted Cox proportional hazards models were fit to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of intestinal obstruction requiring hospitalization. GLP‐1 RAs were associated with an increased risk of intestinal obstruction compared with SGLT‐2 inhibitors (1.9 vs. 1.1 per 1,000 person‐years, respectively; HR: 1.69, 95% CI: 1.04–2.74). The highest HR was observed after 1.6 years of use (HR: 3.48, 95% CI: 1.79–6.79). DPP‐4 inhibitors were also associated with an increased risk (2.7 vs. 1.0 per 1,000 person‐years; HR: 2.59, 95% CI: 1.52–4.42), with the highest HR observed after 1.8 years of use (HR: 9.53, 95% CI: 4.47–20.30). The number needed to harm after 1 year of use was 1,223 and 603 for GLP‐1 RAs and DPP‐4 inhibitors, respectively. In this large real‐world study, GLP‐1 RAs and DPP‐4 inhibitors were associated with an increased risk of intestinal obstruction.
Từ khóa
Tài liệu tham khảo
European Medicine Agency. Pharmacovigilance Risk Assessment Committee (PRAC).Minutes of the meeting –January 7‐10 2013<https://www.ema.europa.eu/en/documents/minutes/minutes‐prac‐meeting‐7‐10‐january‐2013_.pdf>. Accessed July 7 2020.
European Medicine Agency.Pharmacovigilance Risk Assessment Committee (PRAC). Minutes of the meeting –April 7‐10 2015<https://www.ema.europa.eu/en/documents/minutes/minutes‐prac‐meeting‐7‐10‐april‐2015_en.pdf>. Accessed July 7 2020.
Yoshida S., 2014, ‐191: Study on six cases of intestinal obstruction during therapy with DDP‐4 inhibitors, J. Jpn. Diabetes Soc., 57, 311
Hospital Episode Statistics (HES) National Health Services<https://digital.nhs.uk/data‐and‐information/data‐tools‐and‐services/data‐services/hospital‐episode‐statistics>.
Office for National Statistics<https://www.ons.gov.uk/aboutus/whatwedo>.
CPRD linked data<https://cprd.com/linked‐data>.
Gallagher A.M., 2011, 528. Linkage of the General Practice Research Database (GPRD) with other data sources, Pharmacoepidemiol. Drug Saf., 20, 230
Yamada T., 1998, Handbook of Gastroenterology
Yeh D.D., 2021, UpToDate
Bordeianou L., 2021, UpToDate